Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.
Recruitment status was Active, not recruiting
The goal of this study is to determine whether Fluviral, an inactivated, injectable trivalent influenza vaccine (flu shot) is effective in preventing respiratory illnesses that are severe enough to limit normal daily activities and that are shown by virus culture to be caused by influenza viruses. The study will also examine the safety of the vaccine and collect measurements of the immune system responses produced by the vaccine.
Biological: Influenza virus vaccine (Fluviral)
Biological: Saline placebo
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Educational/Counseling/Training
|Official Title:||A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age|
- Incidence of culture confirmed influenza-like illness due to virus strains matching the vaccine during the interval from November to April following treatment.
- Incidence of culture and/or serologically-confirmed influenza-like illness during the interval from November to April following treatment;
- Rate of solicited local and systemic common reactions in days 0 to 3 post-treatment;
- Rate of other adverse events through approximately 135 days post-treatment;
- Rate of four-fold rises in influenza specific antibody titers 21 days after treatment;
- Rate of influenza-specific antibody titers equal to, or greater than, 40 at 21 days after treatment;
- Geometric mean influenza-specific antibody titers at 21 days after treatment.
|Study Start Date:||September 2005|
|Estimated Study Completion Date:||May 2007|
Yearly influenza (flu) epidemics cause a large burden of lost work and school time among younger persons and excess hospitalizations and deaths among the elderly. Injectable flu vaccines are generally believed to be effective, but formal studies using modern culture methods to prove this are limited. This study will compare the rate of respiratory illnesses associated with positive influenza virus cultures in healthy younger adults (a group at low risk for serious influenza complications) who have received Fluviral (an injectable flu vaccine) with the rate of such illnesses in healthy younger adults who have received an injection of saline (salt water). The rate of local vaccine reactions and other symptoms will be compared between the vaccine and salt water groups, and the immune responses to the vaccine measured.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00216242
Show 43 Study Locations
|Study Director:||Nancy Bouveret, MD||ID Biomedical of Quebec|